Cardiac resynchronization therapy is effective even in elderly patients with comorbidities

J Interv Card Electrophysiol. 2010 Jan;27(1):61-8. doi: 10.1007/s10840-009-9449-9. Epub 2009 Nov 25.

Abstract

Purpose: The purpose of this study was to compare the effects of cardiac resynchronization therapy (CRT) in elderly patients (> or =65 years) with younger patients and to assess the impact of comorbidities in CRT remodeling response.

Methods: This is a prospective study of 87 consecutive patients scheduled for CRT who underwent clinical and echocardiographic evaluation before and 6 months after CRT. A reduction in left ventricular end-systolic volume (LVESV) > or =15% after CRT defined remodeling responders, and a reduction of at least one New York Heart Association class defined clinical responders. Multivariate analysis was used to identify independent predictors of non-response to CRT in terms of reverse remodeling.

Results: The mean age was 62 +/- 11 years, with 36 elderly patients (41%). The baseline QRS duration was 145 +/- 32 ms. After CRT, there were significant and similar improvements of left ventricular (LV) ejection fraction, LVESV, LV dP/dt, and mitral regurgitation jet area (JA) between elderly (> or =65 years) and younger (<65 years) patients. The number of clinical and remodeling responders was comparable, and we found no significant differences in unplanned cardiac hospitalizations at 6 months between groups. Independent predictors of lack of remodeling response to CRT were QRS duration <120 ms, LV diastolic diameter >74 mm, and JA >10 cm(2) before CRT, but not comorbidities.

Conclusion: This work suggests that being elderly is not an impediment to CRT success even in the presence of comorbidities.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Atrial Fibrillation / mortality*
  • Atrial Fibrillation / prevention & control*
  • Cardiac Pacing, Artificial / mortality*
  • Comorbidity
  • Female
  • Heart Failure / mortality*
  • Heart Failure / prevention & control*
  • Humans
  • Male
  • Middle Aged
  • Portugal
  • Prevalence
  • Risk Assessment
  • Risk Factors
  • Survival Analysis
  • Survival Rate
  • Treatment Outcome